"Tumor Burden" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Descriptor ID |
D047368
|
MeSH Number(s) |
E05.041.124.892
|
Concept/Terms |
Tumor Burden- Tumor Burden
- Burden, Tumor
- Tumor Load
- Load, Tumor
- Loads, Tumor
- Tumor Loads
Tumor Weight- Tumor Weight
- Tumor Weights
- Weight, Tumor
- Weights, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Burden".
Below are MeSH descriptors whose meaning is more specific than "Tumor Burden".
This graph shows the total number of publications written about "Tumor Burden" by people in this website by year, and whether "Tumor Burden" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 1 | 2 |
2005 | 2 | 3 | 5 |
2006 | 1 | 6 | 7 |
2007 | 3 | 20 | 23 |
2008 | 6 | 12 | 18 |
2009 | 5 | 25 | 30 |
2010 | 8 | 49 | 57 |
2011 | 7 | 52 | 59 |
2012 | 4 | 56 | 60 |
2013 | 6 | 53 | 59 |
2014 | 5 | 67 | 72 |
2015 | 10 | 54 | 64 |
2016 | 5 | 55 | 60 |
2017 | 5 | 44 | 49 |
2018 | 3 | 40 | 43 |
2019 | 5 | 35 | 40 |
2020 | 3 | 31 | 34 |
2021 | 2 | 33 | 35 |
2022 | 0 | 8 | 8 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Burden" by people in Profiles.
-
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Ann Oncol. 2024 Feb; 35(2):183-189.
-
Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases. BMC Surg. 2023 Sep 09; 23(1):271.
-
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. Br J Haematol. 2023 06; 201(6):1192-1199.
-
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
-
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clin Cancer Res. 2022 09 01; 28(17):3797-3803.
-
The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2022 10; 49(12):4241-4251.
-
Imaging characteristics of 4th ventricle subependymoma. Neuroradiology. 2022 Sep; 64(9):1795-1800.
-
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer. 2022 06 15; 128(12):2281-2287.
-
Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. Int J Radiat Oncol Biol Phys. 2022 06 01; 113(2):426-436.
-
Systematic Evaluation of HLA-G 3'Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome. Front Immunol. 2021; 12:817132.